AbbVie's Venclexta-Acalabrutinib Combo Approved for CLL

AbbVie has received FDA approval for its Venclexta-acalabrutinib combination therapy as a first-line treatment for chronic lymphocytic leukemia (CLL).

20 Feb, 11:01 — 20 Feb, 11:01